Why Aptinyx Stock Is Soaring Today

George Budwell, The Motley Fool
·2-min read
Why Aptinyx Stock Is Soaring Today
Why Aptinyx Stock Is Soaring Today

The drugmaker's stock is ripping higher in response to a positive midstage trial for its post-traumatic stress disorder (PTSD) candidate known as NYX-783. Before the opening bell, Aptinyx announced that NYX-783 exhibited statistically significant and clinically meaningful efficacy results in a midstage trial consisting of 153 patients with PTSD. PTSD affects over 8.5 million Americans.